While conventional therapeutic approaches, such as surgery, chemotherapy, radiotherapy, endocrinotherapy, and molecular targeted therapy, have shown significant improvements, particularly in breast cancer with targeted therapies like HER2 and ER, the spotlight seems to be on immunotherapies, considering the amount of potential that has been observed within the literature and the clinical setting. This evidence concerns the gene ESR1 and breast cancer.